With BioNTech’s recent $200 million merger with OncoC4’s cancer drug, the demand for personalised medicines to treat diseases such as cancer continues to grow. Much of this development stems from pharmaceutical biotech companies sharing their cutting-edge bioinformatics data on open-source platforms for others to use.
…